Title | Mitochondrial complex III-derived ROS amplify immunometabolic changes in astrocytes and promote dementia pathology. |
Publication Type | Journal Article |
Year of Publication | 2024 |
Authors | Barnett D, Zimmer TS, Booraem C, Palaguachi F, Meadows SM, Xiao H, Chouchani ET, Orr AG, Orr AL |
Journal | bioRxiv |
Date Published | 2024 Aug 20 |
ISSN | 2692-8205 |
Abstract | Neurodegenerative disorders alter mitochondrial functions, including the production of reactive oxygen species (ROS). Mitochondrial complex III (CIII) generates ROS implicated in redox signaling, but its triggers, targets, and disease relevance are not clear. Using site-selective suppressors and genetic manipulations together with mitochondrial ROS imaging and multiomic profiling, we found that CIII is the dominant source of ROS production in astrocytes exposed to neuropathology-related stimuli. Astrocytic CIII-ROS production was dependent on nuclear factor-κB (NF-κB) and the mitochondrial sodium-calcium exchanger (NCLX) and caused oxidation of select cysteines within immune and metabolism-associated proteins linked to neurological disease. CIII-ROS amplified metabolomic and pathology-associated transcriptional changes in astrocytes, with STAT3 activity as a major mediator, and facilitated neuronal toxicity in a non-cell-autonomous manner. As proof-of-concept, suppression of CIII-ROS in mice decreased dementia-linked tauopathy and neuroimmune cascades and extended lifespan. Our findings establish CIII-ROS as an important immunometabolic signal transducer and tractable therapeutic target in neurodegenerative disease. |
DOI | 10.1101/2024.08.19.608708 |
Alternate Journal | bioRxiv |
PubMed ID | 39229090 |
PubMed Central ID | PMC11370371 |
Grant List | R01 DK123095 / DK / NIDDK NIH HHS / United States R56 AG071966 / AG / NIA NIH HHS / United States F31 AG084165 / AG / NIA NIH HHS / United States R01 AG068091 / AG / NIA NIH HHS / United States K99 AG073461 / AG / NIA NIH HHS / United States R01 AG071966 / AG / NIA NIH HHS / United States |